{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/prescribing-information/angiotensin-ii-receptor-blockers/","result":{"pageContext":{"chapter":{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers","depth":2,"htmlHeader":"<!-- begin field 2126f516-ab2a-4669-8093-a71600db1484 --><h2>Angiotensin-II receptor blockers</h2><!-- end field 2126f516-ab2a-4669-8093-a71600db1484 -->","summary":"","htmlStringContent":"<!-- begin item 27feee74-9abf-4048-b90b-a71600db14bf --><!-- end item 27feee74-9abf-4048-b90b-a71600db14bf -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"69edadb5-bcc6-5904-8297-8de9cbc51ef8","slug":"choice-of-arb","fullItemName":"Choice of ARB","depth":3,"htmlHeader":"<!-- begin field d35d362b-6d3a-4513-9fd8-a71a00cd45e9 --><h3>Which angiotensin-II receptor blocker is recommended?</h3><!-- end field d35d362b-6d3a-4513-9fd8-a71a00cd45e9 -->","summary":"","htmlStringContent":"<!-- begin item dfe9804c-951f-423d-b007-a71a00cd46cd --><!-- begin field 912b7d73-dba3-42d9-84fc-a71a00cd45e9 --><ul><li><strong>The choice of angiotensin-II receptor blocker (also known as angiotensin-II receptor antagonist) usually depends on the person's co-morbidities, local recommendations, and cost.</strong></li><li>Where possible, prescribe a drug that is taken only once a day and prescribe non-proprietary drugs where these are appropriate and minimise cost.<ul><li>For people with heart failure and hypertension, candesartan, losartan, and valsartan may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li></ul></li><li>For people who have diabetes and hypertension, candesartan, irbesartan, losartan, or valsartan may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>]</p><!-- end field 912b7d73-dba3-42d9-84fc-a71a00cd45e9 --><!-- end item dfe9804c-951f-423d-b007-a71a00cd46cd -->","subChapters":[]},{"id":"720adad1-761a-508f-84d3-368cc2fc8112","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b6f3d5c6-6be6-4194-85f8-a71a00cd7a46 --><h3>Contraindications and cautions</h3><!-- end field b6f3d5c6-6be6-4194-85f8-a71a00cd7a46 -->","summary":"","htmlStringContent":"<!-- begin item 47b9af79-183b-4feb-9c49-a71a00cd66cc --><!-- begin field a221c6df-7440-4722-92f3-a71a00cd7a46 --><ul><li><strong>Use of angiotensin-II receptor blockers (ARBs) is contraindicated in:</strong><ul><li>People with diabetes mellitus, or with an estimated glomerular filtration rate (eGFR) less than 60 mL/minute/1.73m<sup>2</sup>, who are also taking aliskiren.</li><li>Pregnant women and those planning a pregnancy — due to risks to the fetus. Treatment with an ARB should ideally be stopped as soon as pregnancy is detected and, if appropriate, alternative treatment should be started.<ul><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> and <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a>.</li></ul></li><li>Breastfeeding women — ARBs are not recommended as there is limited information on their safety.</li></ul></li><li><strong>ARBs should be used with caution in people:</strong><ul><li>Of black African or Caribbean origin or with primary aldosteronism — may respond less well to ARBs.</li><li>With renal impairment — hyperkalaemia and other adverse effects are more common, and the dose may need to be reduced. </li><li>With renal artery stenosis.</li><li>With a history of angioedema.</li><li>With hypertrophic cardiomyopathy.</li><li>With aortic or mitral valve stenosis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field a221c6df-7440-4722-92f3-a71a00cd7a46 --><!-- end item 47b9af79-183b-4feb-9c49-a71a00cd66cc -->","subChapters":[]},{"id":"ef5a6091-e922-5e72-a185-0d6db9fa5cd3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 39ccf5dc-1ad7-4b71-9c8c-a71a00ce18bc --><h3>Adverse effects</h3><!-- end field 39ccf5dc-1ad7-4b71-9c8c-a71a00ce18bc -->","summary":"","htmlStringContent":"<!-- begin item c7d732c3-18e0-48f7-bb95-a71a00ce1a0a --><!-- begin field bcec1e1a-db5a-4328-a2dc-a71a00ce18bc --><p><strong>Adverse effects of angiotensin II receptor blockers (ARBs) include:</strong></p><ul><li><strong>Renal impairment </strong>— monitor renal function 1–2 weeks after starting an ARB, after each increase in dose, and regularly throughout treatment.</li><li><strong>Hyperkalaemia </strong>— monitor<strong> </strong>serum electrolytes 1–2 weeks after starting an ARB, after each increase in dose, and regularly throughout treatment.</li><li><strong>Angioedema </strong>— ARBs can cause a non-allergic drug reaction which can precipitate angioedema. Stop ARB treatment immediately, and consider starting an alternative drug treatment. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Dizziness </strong>— dizziness due to hypotension occurs most commonly in people with intravascular volume depletion, such as those taking high dose diuretics.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field bcec1e1a-db5a-4328-a2dc-a71a00ce18bc --><!-- end item c7d732c3-18e0-48f7-bb95-a71a00ce1a0a -->","subChapters":[]},{"id":"239a1fb1-44b4-555f-bb7e-33a1e1041a1b","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4e5cb062-0335-4726-a59e-a7870157b179 --><h3>Drug interactions</h3><!-- end field 4e5cb062-0335-4726-a59e-a7870157b179 -->","summary":"","htmlStringContent":"<!-- begin item e063dd4e-23c2-4709-beef-a7870157ab25 --><!-- begin field 62ab7b7e-70a6-4c8a-b751-a7870157b179 --><p><strong>Drug interactions with angiotensin-II receptor blockers (ARBs) include:</strong></p><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors and aliskerin</strong> — concomitant use of two drugs affecting the renin-angiotensin system increases the risk of hyperkalaemia, hypotension, and renal impairment.<ul><li>People with diabetic neuropathy are particularly susceptible to developing hyperkalaemia and should not receive combination treatment.</li><li>For people for whom combination therapy is considered essential, specialist supervision with close monitoring of blood pressure, renal function, and electrolytes is recommended - monitoring should be carried out when treatment commences, then monthly, and also after any change in dose or intercurrent illness.</li></ul></li><li><strong>Diuretics</strong> — prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension.</li><li><strong>Lithium </strong>— reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration. Monitoring of serum lithium levels is therefore recommended.</li><li><strong>Non-steroidal anti-inflammatory drugs </strong>—<strong> </strong>attenuation of antihypertensive effect may occur and there may be an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in people with poor pre-existing renal function and elderly people. Consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter, and people should be counselled regarding the importance of adequate hydration.</li><li><strong>Amiloride, ciclosporin, eplerenone, heparins, potassium canrenoate, potassium salts, spironolactone, tacrolimus, triamterene,</strong> <strong>trimethoprim</strong> — increased risk of hyperkalaemia. Monitoring of electrolytes and renal function may be advised.</li><li><strong>Alpha-blockers, alprostadil, antipsychotics, anxiolytics, beta-blockers, baclofen, calcium channel blockers, clonidine, co-beneldopa, co-careldopa, diazoxide, hydralazine, hypnotics, levodopa, methyldopa, minoxidil, monoamine oxidase inhibitors, moxisylyte, moxonidine, nitrates, sodium nitroprusside, tizanidine </strong>— enhanced hypotensive effect.</li><li><strong>Corticosteroids, oestrogens</strong> — hypotensive effect antagonised with concomitant use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>]</p><!-- end field 62ab7b7e-70a6-4c8a-b751-a7870157b179 --><!-- end item e063dd4e-23c2-4709-beef-a7870157ab25 -->","subChapters":[]},{"id":"497897f9-31b9-55ce-9e2a-8d8e047deedc","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 500772b6-93ad-4904-b81b-a71a00cdbbed --><h3>Dose and titration</h3><!-- end field 500772b6-93ad-4904-b81b-a71a00cdbbed -->","summary":"","htmlStringContent":"<!-- begin item 1cccba56-7fef-45e9-97a9-a71a00cdbaf6 --><!-- begin field b2c8c080-e661-4f94-a4d0-a71a00cdbbed --><ul><li>Start with a low dose of angiotensin-II receptor blocker (ARB) and titrate upwards every 4 weeks until the target blood pressure has been achieved, or the person has reached the maximum prescribable or tolerated dose of ARB.</li><li>Advise the person to take the first dose in the evening.<ul><li>If the drug is well tolerated, subsequent doses should be taken in the morning.</li><li>If symptoms of hypotension occur, advise them to go to bed and take no further doses until they have been reviewed.</li></ul></li><li>Monitor renal function and serum electrolytes 1–2 weeks after each upward titration. Monitor blood pressure 4 weeks after each dose titration.<ul><li>For more information, see <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/prescribing-information/angiotensin-converting-enzyme-inhibitors/#monitoring\">Monitoring</a>.</li></ul></li><li><strong>For people who are taking diuretics:</strong><ul><li>If the person is taking a low-dose diuretic (for example bendroflumethiazide 2.5 mg daily), give a low starting dose of an ARB.</li><li>Refer people who are taking high-dose diuretics (equivalent to 80 mg furosemide or more) to secondary care to initiate ARB treatment.</li></ul></li><li>Details of the usual starting, maintenance, and maximum doses of ARBs are given in the table.</li></ul><p><strong>Table 2.</strong> Usual starting, maintenance, and maximum doses of ARBs for hypertension.</p><table><thead><tr><th scope=\"col\">ARB</th><th scope=\"col\">Low starting doses*</th><th scope=\"col\">Usual starting dose</th><th scope=\"col\">Usual maintenance dose</th><th scope=\"col\">Maximum dose</th></tr></thead><tbody><tr><td>Azilsartan</td><td>20 to 40 mg once a day</td><td>40 mg once a day</td><td>40 to 80 mg once a day</td><td>80 mg once a day</td></tr><tr><td>Candesartan</td><td>4 mg once a day</td><td>8 mg once a day</td><td>8 mg once a day</td><td>32 mg once a day</td></tr><tr><td>Eprosartan</td><td>600 mg once a day</td><td>600 mg once a day</td><td>600 mg once a day</td><td>600 mg once a day</td></tr><tr><td>Irbesartan</td><td>75 mg once a day</td><td>150 mg once a day</td><td>150 mg once a day</td><td>300 mg once a day</td></tr><tr><td>Losartan</td><td>25 mg once a day</td><td>50 mg once a day</td><td>50 mg once a day</td><td>100 mg once a day</td></tr><tr><td>Olmesartan</td><td>10 mg once a day</td><td>10 mg once a day</td><td>20 mg once a day</td><td>40 mg once a day</td></tr><tr><td>Telmisartan</td><td>20 mg once a day</td><td>20 to 40 mg once a day</td><td>40 mg once a day</td><td>80 mg once a day</td></tr><tr><td>Valsartan</td><td>40 mg once a day</td><td>80 mg once a day</td><td>80 to 160 mg once a day</td><td>320 mg once a day</td></tr><tr><td colspan=\"5\">* Lower starting doses are required for people who are more prone to the adverse effects of ARBs (such as elderly, frail, or renally impaired people or people who are taking a diuretic).</td></tr><tr><td colspan=\"5\"><strong>Information from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</td></tr></tbody></table><!-- end field b2c8c080-e661-4f94-a4d0-a71a00cdbbed --><!-- end item 1cccba56-7fef-45e9-97a9-a71a00cdbaf6 -->","subChapters":[]},{"id":"89c46e82-f393-5090-aa3a-94ef5a163a6d","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 97fc2ab5-ffe8-4a67-b724-a71a00cdd1d8 --><h3>Monitoring</h3><!-- end field 97fc2ab5-ffe8-4a67-b724-a71a00cdd1d8 -->","summary":"","htmlStringContent":"<!-- begin item 11fa5e42-7b8a-49f7-a5ac-a71a00cdd36b --><!-- begin field 948437a0-c698-4d3d-ac40-a71a00cdd1d8 --><ul><li>Measure renal function (serum creatinine and estimated glomerular filtration rate) and serum electrolytes before starting treatment.</li><li>Check renal function and serum electrolytes 1–2 weeks after starting treatment and 1–2 weeks after each dose increase. Thereafter, check renal function and serum electrolytes annually unless clinical judgement or abnormal blood testing parameters indicate a need for more frequent monitoring. </li><li>Check blood pressure 4 weeks after each dose titration.</li><li>For people who are at higher risk of hyperkalaemia or deteriorating renal function (for example those with peripheral vascular disease, diabetes mellitus, or pre-existing renal impairment or older people), consider checking renal function and serum electrolytes sooner (within 1 week).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">Smellie et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">London and South East Medicines Information Service et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 948437a0-c698-4d3d-ac40-a71a00cdd1d8 --><!-- end item 11fa5e42-7b8a-49f7-a5ac-a71a00cdd36b -->","subChapters":[]},{"id":"425e7747-910e-5fd7-a248-953e6a17a051","slug":"managing-abnormal-results","fullItemName":"Managing abnormal results","depth":3,"htmlHeader":"<!-- begin field 0e7e3aeb-d185-4877-8e78-a71a00cdf8db --><h3>How should I manage abnormal test results in people on an ARB?</h3><!-- end field 0e7e3aeb-d185-4877-8e78-a71a00cdf8db -->","summary":"","htmlStringContent":"<!-- begin item f672d169-d3b8-4f5b-b70c-a71a00cdf9c5 --><!-- begin field a74af6fa-7ec1-4314-9f84-a71a00cdf8db --><ul><li>Some increase in serum creatinine and potassium is expected after starting or increasing the dose of an angiotensin-II receptor blocker (ARB).</li><li><strong>If the estimated glomerular filtration rate (eGFR) decreases by less than 25%, or serum creatinine increases</strong><strong> by less than 30%:</strong><ul><li>Do not modify the ARB dose and recheck levels in a further 1–2 weeks.</li></ul></li><li><strong>If eGFR decreases by 25% or more, or serum creatinine </strong><strong>increases</strong><strong> by 30% or more:</strong><ul><li>Investigate other causes of deteriorating renal function, such as volume depletion.</li><li>Stop or reduce the dose of the following drugs (where appropriate) if the person is taking them:<ul><li>Nephrotoxic drugs (such as nonsteroidal anti-inflammatory drugs [NSAIDs]).</li><li>Vasodilators (such as calcium-channel blockers, nitrates).</li><li>Potassium supplements or potassium-sparing diuretics.</li><li>Diuretics (consider dose reduction if the person is hypovolaemic).</li></ul></li><li>If the decrease in eGFR or the increase in serum creatinine persists despite these measures:<ul><li>Stop the ARB <em>or</em></li><li>Reduce the dose to a previously tolerated lower dose and recheck levels in 5–7 days (add an alternative antihypertensive medication if required).</li></ul></li></ul></li><li><strong>If serum potassium is 5.0 mmol/L or above:</strong><ul><li>Investigate other causes of hyperkalaemia and treat accordingly.</li><li>Stop or reduce the dose of potassium-sparing diuretics (amiloride, triamterene, spironolactone) or nephrotoxic drugs (such as NSAIDs).</li></ul></li><li><strong>If serum potassium persists between 5.0 and 5.9 mmol/L despite these measures, </strong>reduce the dose of the ARB to a previously tolerated lower dose and recheck levels in 5–7 days.</li><li><strong>Stop the ARB if serum potassium persists above 6 mmol/L despite these measures.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2014</a>]</p><!-- end field a74af6fa-7ec1-4314-9f84-a71a00cdf8db --><!-- end item f672d169-d3b8-4f5b-b70c-a71a00cdf9c5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}